Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

More organoids, more options
October 2019
SHARING OPTIONS:

MANCHESTER, U.K.—Epistem Limited and Hubrecht Organoid Technology (HUB) have completed an agreement that will expand Epistem’s in-vitro model portfolio by the delivery of an increased range of multi-species organoid models. The services involved focus on identifying off-target or off-tissue intestinal toxicities associated with various therapeutics. Financial details were not disclosed.
 
“Organoids provide valuable insight into toxicity when analyzed using techniques such as gene expression profiling, imaging and FACs analysis. They will help, alongside well-designed in-vivo studies, enable our customers to make more informed decisions and improve the efficiency of their drug development process. We are also developing complementary services to investigate drug and microbiota effects on barrier function, inflammatory signals and early fibrosis,” said Dr. Catherine Booth, CEO of Epistem.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.